Editorial Comment

Retrospective evaluations of the treatment of the primary tumor in the setting of metastatic hormone sensitive prostate cancer (mHSPC) are prevalent in the recent literature. The majority of these reports have favored the addition of local therapy1 and form the hypothesis generating support for recently completed and ongoing prospective randomized studies.2,3 Interestingly, in the present retrospective study, cancer-specific survival was not improved with local therapy. This is intriguing since the patients were subject to similar selection biases present in other retrospective reviews favoring local therapy.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research

Related Links:

Treatments for advanced prostate cancer that suppress testosterone, a hormone (also called an androgen) that drives the malignant cells to grow and spread, are collectively referred to as androgen deprivation therapies, or ADT. These therapies can significantly extend lifespans in men who have the disease, but they also have a range of challenging side effects. In 2004, Dr. Marc Garnick, Gorman Brothers Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center, and editor in chief of HarvardProstateKnowledge.org, reported that in some men, an ADT drug called aberelix lengthens the time it tak...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Health Living With Prostate Cancer Men's Health Prostate Health Prostate Knowledge Treatments HPK Source Type: blogs
PROSTATE cancer develops when the cells in the prostate start to grow in an uncontrolled way. Knowing the signs and symptoms will ensure early treatment and survival. A certain sign in your semen is a warning sign.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Authors: Bonk S, Kluth M, Hube-Magg C, Polonski A, Soekeland G, Makropidi-Fraune G, Möller-Koop C, Witt M, Luebke AM, Hinsch A, Burandt E, Steurer S, Clauditz TS, Schlomm T, Perez D, Graefen M, Heinzer H, Huland H, Izbicki JR, Wilczak W, Minner S, Sauter G, Simon R Abstract To assess the prognostic and diagnostic utility of PSA immunostaining, tissue microarrays containing 17,747 prostate cancers, 3,442 other tumors from 82 different (sub) types and 608 normal tissues were analyzed at two different antibody concentrations (1:100 and 1:800). In normal tissues, PSA expression was limited to prostate epithelial c...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Bayer data at ESMO 2019 highlights innovation in cancer researchNew data for larotrectinib on durability of response in patients with TRK fusion cancer to be presented in a poster discussion on September 28 / Data from Bayer's prostate cancer franchise to be presented, including clinical relevance of drug-drug interactions in men with nmCRPC taking darolutamide and real-world data and pain evalutation data in men with mCRPC treated with radium-223 dichloride / New analyses from the Phase II study REGOBONE evaluating the efficacy and safety of regorafenib in patients with rare locally advanced or metastatic relapsed chondro...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news
Patients with non-Hodgkin's lymphoma who received radiation 30 days or less...Read more on AuntMinnie.comRelated Reading: ASTRO: AI predicts side effects from radiation therapy ASTRO: Is hormone therapy after prostate surgery needed? ASTRO: SABR generates immune response to prostate cancer ASTRO: Cervical cancer deaths rise as women's centers close ASTRO: Whole, partial breast RT yield similar cosmetic results
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Cancers, Vol. 11, Pages 1405: Neuroendocrine Differentiation of Prostate Cancer—An Intriguing Example of Tumor Evolution at Play Cancers doi: 10.3390/cancers11101405 Authors: Patel Chugh Tripathi Our understanding of neuroendocrine prostate cancer (NEPC) has assumed a new perspective in light of the recent advances in research. Although classical NEPC is rarely seen in the clinic, focal neuroendocrine trans-differentiation of prostate adenocarcinoma occurs in about 30% of advanced prostate cancer (PCa) cases, and represents a therapeutic challenge. Even though our knowledge of the mechanisms that media...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Publication date: Available online 19 September 2019Source: European UrologyAuthor(s): Nicolai A. Huebner, Shahrokh F. Shariat
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 18 September 2019Source: European UrologyAuthor(s): Mary-Ellen Taplin, Emmanueal S. Antonarakis, Karen J. Ferrante, Kerry Horgan, Brent Blumenstein, Fred Saad, Jun Luo, Johann S. de BonoAbstractBackground: Detection of androgen receptor (AR) splice variant-7 (AR-V7) messenger RNA (mRNA) in circulating tumor cells (CTCs) is associated with a suboptimal response to abiraterone and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). Galeterone inhibits CYP17 and AR, and induces AR protein degradation. We hypothesized that galeterone would be clinically superior to enzalu...
Source: European Urology - Category: Urology & Nephrology Source Type: research
DiscussionPCOs measured in studies of mpMRI or MRI-guided biopsy thus far have mostly been physical outcomes, with some evidence that MRI tests are associated with less frequent adverse outcomes compared with transrectal ultrasound biopsy. There was very little evidence for the effect of mpMRI and MRI-guided biopsy on emotional, cognitive, social, or behavioral outcomes.
Source: Journal of the American College of Radiology - Category: Radiology Source Type: research
Condition:   Prostate Cancer Interventions:   Drug: enzalutamide;   Drug: enzalutamide Placebo;   Drug: digoxin;   Drug: rosuvastatin Sponsors:   Astellas Pharma Global Development, Inc.;   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chad Health | Hormones | Prostate Cancer | Study | Urology & Nephrology